All Articles

Results of the multicohort phase 1b ACTION trial indicated that anlotinib plus TQB2450 shows encouraging antitumor activity and tolerable toxicity in patients with recurrent advanced ovarian cancer.

Pooled analysis data from the PRIMA, NOVA, and NORA trials suggest that patients with BRCA-mutated ovarian cancer derive a significant progression-free survival benefit from niraparib maintenance treatment, with no new safety signals.

Findings of a retrospective study indicate that patients with platinum-sensitive recurrent ovarian cancer were increasingly being administered maintenance therapy after second-line or third-line platinum-based chemotherapy regardless of biomarker status.

This review outlines the disruptions to delivery of cancer care caused by the COVID pandemic, including delays in diagnosis, surgery, and treatment, as well as the psychological impact.

The findings of a prospective study suggest that immunologic response to SARS-CoV-2 vaccination is lower among patients with ovarian cancer who are receiving treatment compared with healthy volunteers, indicating that such patients should maintain precautions against COVID-19 despite vaccination.

Results from a retrospective analysis indicate that health education, using a clinical nursing pathway, results in a more effective understanding of ovarian cancer, reduced psychological burden, improved sleep quality, decreased incidence of complications, improved self-care agency, and improved quality of life among patients with ovarian cancer.

Results of the C-MOnGene study support the adoption of a collaborative oncogenetic model that provides flexible, patient-centered, and efficient genetic counseling and testing for hereditary breast and ovarian cancer and serves as an example for other institutions to incorporate these aspects into their oncology care.

Findings of a national survey of US ovarian cancer programs identified several patient care deficits, including a greater need for the integration of palliative care, social work, dietetics, and financial counseling, and the expansion of clinical trials and genetic testing/counseling.

In 2021, the COVID-19 pandemic continued to impact the practice of medicine and dissemination of treatment advances presented in scientific forums.

Olaparib was more cost-effective, compared with niraparib, as maintenance therapy for patients with recurrent platinum-sensitive ovarian cancer, as determined by a model-based analysis.